Adcetris for Hodgkin Lymphoma (post-ASCT consolidation) – Details


( Last Updated : July 7, 2016)
Generic Name:
Brentuximab vedotin
Project Status:
Withdrawn
Manufacturer:
Seattle Genetics Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0086-000

Details


Tumour Type:
Lymphoma
Indications:
Hodgkin Lymphoma (post-ASCT consolidation)
Funding Request:
For post-ASCT consolidation treatment of patients with Hodgkin Lymphoma (HL) at high risk of relapse or progression
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
Seattle Genetics Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Seattle Genetics Inc. has requested a voluntary withdrawal of the submission for brentuximab vedotin (Adcetris) for Hodgkin Lymphoma (post-ASCT consolidation) as the Category 2 submission requirements for a pre-NOC submission cannot be met at this time. As per pCODR Procedures B3.1.6.2 b), the pCODR program has stopped the review. The pCODR Provincial Advisory Group has agreed with the manufacturer's request.
Funding Request:
For post-ASCT consolidation treatment of patients with Hodgkin Lymphoma (HL) at high risk of relapse or progression

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.